Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | SUITE 650, 4275 EXECUTIVE SQUARE LA JOLLA CA 92037 |
Tel: | N/A |
Website: | https://medicinova.com |
IR: | See website |
Key People | ||
Yuichi Iwaki President, Chief Executive Officer, Director | Jason J. Kruger Chief Financial Officer | Kazuko Matsuda Chief Medical Officer, Director | David H. Crean Chief Business Officer |
Business Overview |
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. |
Financial Overview |
For the fiscal year ended 31 December 2023, Medicinova Inc revenues increased from $0K to $1M. Net loss decreased 39% to $8.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development and patents decrease of 39% to $5.4M (expense), Interest Income increase from $810K to $1.8M (income), General decrease of 9% to $4.4M (expense). |
Employees: | 13 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $15.46M as of Dec 31, 2023 |
Annual revenue (TTM): | $1.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$9.88M as of Dec 31, 2023 |
Net annual income (TTM): | -$8.57M as of Dec 31, 2023 |
Free cash flow (TTM): | -$7.43M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 49,046,246 as of Feb 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |